Burden and trends of hospitalisations associated with pulmonary non-tuberculous mycobacterial infections in Germany, 2005–2011

BMC Infectious Diseases

Tobias Welte⁵  Dirk Wagner²  Hendrik Suhling⁵  Jessica Rademacher⁵  Mathias W Pletz⁴  Andrés de Roux³  Franz-Christoph Bange¹  Rosa-Marie Apel⁵  Felix C Ringshausen⁵ 

[1] Institute for Medical Microbiology and Hospital Epidemiology, Hannover Medical School, Hannover, Germany;Centre for Infectious Diseases and Travel Medicine and Centre for Chronic Immunodeficiency, University Hospital Freiburg, Freiburg, Germany;Centre for Respiratory Medicine at the Charlottenburg Castle, Berlin, Germany;Centre for Infectious Diseases and Infection Control, Jena University Hospital, Jena, Germany;Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany

关键词: Tuberculosis;    Non-tuberculous mycobacteria;    Mycobacterium avium complex;    International classification of diseases;    Health services research;    Cystic fibrosis;    COPD epidemiology;    Clinical epidemiology;    Bronchiectasis;    Atypical mycobacterial infection;   

Others  :  1148301
DOI  :  10.1186/1471-2334-13-231

 received in 2013-03-25, accepted in 2013-05-14,  发布年份 2013

【 摘 要 】

Background

Representative population-based data on the epidemiology of pulmonary non-tuberculous mycobacterial (PNTM) infections in Europe are limited. However, these data are needed in order to optimise patient care and to facilitate the allocation of healthcare resources. The aim of the present study was to investigate the current burden and the trends of PNTM infection-associated hospitalisations in Germany.

Methods

International Classification of Diseases, 10th revision (ICD-10) discharge diagnosis codes were extracted from the official nationwide diagnosis-related groups (DRG) hospital statistics in order to identify PNTM infection-associated hospitalisations (ICD-10 code A31.0) between 2005 and 2011. Poisson log-linear regression analysis was used to assess the significance of trends.

Results

Overall, 5,959 records with PNTM infection as any hospital discharge diagnosis were extracted from more than 125 million hospitalisations. The average annual age-adjusted rate was 0.91 hospitalisations per 100,000 population. Hospitalisation rates increased during the study period for both males and females, with the highest rate of 3.0 hospitalisations per 100,000 population among elderly men, but the most pronounced average increase of 6.4%/year among females, particularly those of young and middle age, and hospitalisations associated with cystic fibrosis. Overall, chronic obstructive pulmonary disease (COPD) was the most frequent PNTM infection-associated condition in 28.9% of hospitalisations and also showed a significant average annual increase of 4.8%.

Conclusions

The prevalence of PNTM infection-associated hospitalisations is steadily increasing in Germany. COPD is currently the most important associated condition. Our population-based study provides evidence of a changing epidemiology of PNTM infections and highlights emerging clinical implications.

【 授权许可】

   
2013 Ringshausen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF: An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007, 175(4):367-416.
• [2]Sexton P, Harrison AC: Susceptibility to nontuberculous mycobacterial lung disease. Eur Respir J 2008, 31(6):1322-1333.
• [3]Cassidy PM, Hedberg K, Saulson A, McNelly E, Winthrop KL: Nontuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology. Clin Infect Dis 2009, 49(12):e124-e129.
• [4]Daley CL, Griffith DE: Pulmonary non-tuberculous mycobacterial infections. Int J Tuberc Lung Dis 2010, 14(6):665-671.
• [5]Thomson RM: Changing epidemiology of pulmonary nontuberculous mycobacteria infections. Emerg Infect Dis 2010, 16(10):1576-1583.
• [6]Hoefsloot W, van Ingen J, Andrejak C, Ängeby K, Bauriaud R, Bemer P, Beylis N, Boeree MJ, Cacho J, Chihota V: The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: a NTM-NET collaborative study. Eur Respir J 2013. in press (http://erj.ersjournals.com/content/early/2013/04/17/09031936.00149212.long webcite)
• [7]Freeman J, Morris A, Blackmore T, Hammer D, Munroe S, McKnight L: Incidence of nontuberculous mycobacterial disease in New Zealand, 2004. N Z Med J 2007, 120(1256):U2580.
• [8]Marras TK, Chedore P, Ying AM, Jamieson F: Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997 2003. Thorax 2007, 62(8):661-666.
• [9]Billinger ME, Olivier KN, Viboud C, de Oca RM, Steiner C, Holland SM, Prevots DR: Nontuberculous mycobacteria-associated lung disease in hospitalized persons, United States, 1998–2005. Emerg Infect Dis 2009, 15(10):1562-1569.
• [10]van Ingen J, Bendien SA, de Lange WC, Hoefsloot W, Dekhuijzen PN, Boeree MJ, van Soolingen D: Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands. Thorax 2009, 64(6):502-506.
• [11]Andrejak C, Thomsen VO, Johansen IS, Riis A, Benfield TL, Duhaut P, Sorensen HT, Lescure FX, Thomsen RW: Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. Am J Respir Crit Care Med 2010, 181(5):514-521.
• [12]Lai CC, Tan CK, Chou CH, Hsu HL, Liao CH, Huang YT, Yang PC, Luh KT, Hsueh PR: Increasing incidence of nontuberculous mycobacteria, Taiwan, 2000–2008. Emerg Infect Dis 2010, 16(2):294-296.
• [13]Prevots DR, Shaw PA, Strickland D, Jackson LA, Raebel MA, de Oca Montes R, Blosky MA, Shea YR, Seitz AE, Holland SM: Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med 2010, 182((7):970-976.
• [14]Winthrop KL, McNelley E, Kendall B, Marshall-Olson A, Morris C, Cassidy M, Saulson A, Hedberg K: Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. Am J Respir Crit Care Med 2010, 182(7):977-982.
• [15]Dailloux M, Abalain ML, Laurain C, Lebrun L, Loos-Ayav C, Lozniewski A, Maugein J: Respiratory infections associated with nontuberculous mycobacteria in non-HIV patients. Eur Respir J 2006, 28(6):1211-1215.
• [16]Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR: Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med 2012, 185(8):881-886.
• [17]The Information System of the Federal Health Monitoring. http://www.gbe-bund.de/ webcite
• [18]Facts & Figures – State & Society – Federal Statistical Office (Destatis). http://www.destatis.de/EN/FactsFigures/SocietyState/SocietyState.html webcite
• [19]Moore JE, Kruijshaar ME, Ormerod LP, Drobniewski F, Abubakar I: Increasing reports of non-tuberculous mycobacteria in England, Wales and Northern Ireland, 1995–2006. BMC Publ Health 2010, 10:612. BioMed Central Full Text
• [20]Winthrop KL: Pulmonary disease due to nontuberculous mycobacteria: an epidemiologist’s view. Future Microbiol 2010, 5(3):343-345.
• [21]Al Houqani M, Jamieson F, Chedore P, Mehta M, May K, Marras TK: Isolation prevalence of pulmonary nontuberculous mycobacteria in Ontario in 2007. Can Respir J 2011, 18(1):19-24.
• [22]Al-Houqani M, Jamieson F, Mehta M, Chedore P, May K, Marras TK: Aging, COPD, and other risk factors do not explain the increased prevalence of pulmonary Mycobacterium avium complex in Ontario. Chest 2012, 141(1):190-197.
• [23]Andrejak C, Nielsen R, Thomsen VO, Duhaut P, Sorensen HT, Thomsen RW: Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax 2013, 68(3):256-262.
• [24]van Ingen J, Hoefsloot W, Dekhuijzen PN, Boeree MJ, van Soolingen D: The changing pattern of clinical Mycobacterium avium isolation in the Netherlands. Int J Tuberc Lung Dis 2010, 14(9):1176-1180.
• [25]Global Health Observatory Data Repository. http://apps.who.int/ghodata/ webcite
• [26]O’Malley KJ, Cook KF, Price MD, Wildes KR, Hurdle JF, Ashton CM: Measuring diagnoses: ICD code accuracy. Health Serv Res 2005, 40(5 Pt 2):1620-1639.
• [27]Winthrop KL, Varley CD, Ory J, Cassidy PM, Hedberg K: Pulmonary disease associated with nontuberculous mycobacteria, Oregon, USA. Emerg Infect Dis 2011, 17(9):1760-1761.
• [28]Adjemian J, Olivier KN, Seitz AE, Falkinham JO 3rd, Holland SM, Prevots DR: Spatial clusters of nontuberculous mycobacterial lung disease in the United States. Am J Respir Crit Care Med 2012, 186(6):553-558.
• [29]Versorgungsbericht 2010 - ambulante Pneumologie. Heidenheim: Bundesverband der Pneumologen (BdP) in Kooperation mit dem Wissenschaftlichen Informationsnetzwerk der niedergelassenen Pneumologen (WINPNEU); 2011.
• [30]Kim RD, Greenberg DE, Ehrmantraut ME, Guide SV, Ding L, Shea Y, Brown MR, Chernick M, Steagall WK, Glasgow CG: Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med 2008, 178(10):1066-1074.
• [31]Ballarino GJ, Olivier KN, Claypool RJ, Holland SM, Prevots DR: Pulmonary nontuberculous mycobacterial infections: antibiotic treatment and associated costs. Respir Med 2009, 103(10):1448-1455.
• [32]Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, Criner GJ, Curtis JL, Dransfield MT, Han MK, Lazarus SC: Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011, 365(8):689-698.
• [33]Southern KW, Barker PM, Solis-Moya A, Patel L: Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2012, 11:CD002203.
• [34]Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, Milne D, Fergusson W, Tuffery C, Sexton P: Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012, 380(9842):660-667.
• [35]Renna M, Schaffner C, Brown K, Shang S, Tamayo MH, Hegyi K, Grimsey NJ, Cusens D, Coulter S, Cooper J: Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest 2011, 121(9):3554-3563.